Navigation Links
NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
Date:4/22/2009

ce, they have published successful results of a Phase II clinical trial in ear infections (otitis externa) using NCT. NovaBay expects Alcon, its licensee for the use of Aganocide compounds in the treatment of eye, ear, and sinus infections, to start human trials in the ear during 2009 with NovaBay's lead Aganocide compound NVC-422. Professors Nagl and Gottardi have also pursued studies with NCT in additional indications that can provide NovaBay with guidance in its future clinical programs.

In addition to the research agreement, NovaBay has obtained an exclusive license to a broad portfolio of intellectual property covering uses of NCT compounds. As a result, NovaBay has augmented its composition of matter patent for Aganocide compounds with a license to a series of patents covering key potential uses, including utility of NCT compounds in pulmonary diseases and their potential use in major animal health markets, such as mastititis.

"We are very excited to collaborate with this world-class research team, and pleased to draw on the extensive experience of Professors Gottardi and Nagl in understanding the role of our class of molecules in the prevention and treatment of infectious diseases," said Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay. "We look forward to building on their work to further expand the range of clinical opportunities provided by our Aganocide compound platform."

"We expect to substantially broaden NovaBay's efforts by leveraging the resources and expertise at the Medical University of Innsbruck," said Dr. Bez Khosrovi, Vice President of Research and Development at NovaBay. "We see this collaboration as adding significant depth to our preclinical and clinical development programs and to the continued exploration of the properties of our Aganocide compounds. We expect that our joint efforts will provide important information that may further accelerate our efforts to develop
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  Decision Resources ... specialties (medical oncology, hematology-oncology, rheumatology, gastroenterology, endocrinology and ... trials that a biosimilar has been assessed in ... product they choose to prescribe. ... report entitled Acceptance of Biosimilars Across ...
(Date:8/27/2014)... , Aug. 27, 2014   Los Angeles orthodontics ... AcceleDent® Aura to patients who want to make their ... available at the OrthoSpaceship, all patients have a powerful ... This system can be used by most patients with ... of progress by using the AcceleDent® Aura system for ...
(Date:8/27/2014)... Decision Resources Group finds that the intense ... health system and hospital sector in recent ... Methodist Le Bonheur Healthcare and Baptist Memorial Health Care ... care. In addition, a national contract recently signed between ... enrollment in the Memphis market, ...
Breaking Medicine Technology:Surveyed Physicians Expect to Choose Between Future Biosimilars Based on Robustness and Number of Clinical Trials 2Los Angeles Orthodontist, Dr. Isaac Hakim, is Now Offering AcceleDent Aura 2Memphis-area Health Systems Turn Attention to Clinical Integration 2
... 15, 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiac ... quarter ended June 30, 2011. More details on the financial ... 10-Q, filed today with the Securities and Exchange Commission. ... a top 5 global pharmaceutical company for two Phase I ...
... 15, 2011 For the first time, the ... guidance clarifying how benefit-risk determinations are made during ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Released today, ... the regulatory pathway for high-risk medical devices. The ...
Cached Medicine Technology:NewCardio Announces Financial Results for Its 2011 Second Quarter 2NewCardio Announces Financial Results for Its 2011 Second Quarter 3NewCardio Announces Financial Results for Its 2011 Second Quarter 4NewCardio Announces Financial Results for Its 2011 Second Quarter 5NewCardio Announces Financial Results for Its 2011 Second Quarter 6NewCardio Announces Financial Results for Its 2011 Second Quarter 7NewCardio Announces Financial Results for Its 2011 Second Quarter 8FDA Proposes Guidelines That Clarify Benefit-Risk Determinations for Medical Devices 2
(Date:8/27/2014)... Tejal K. Gandhi, MD, MPH, CPPS, president ... the NPSF Lucian Leape Institute, is among the 100 Most ... of Modern Healthcare magazine. Also on the list are NPSF ... MBA; NPSF Lucian Leape Institute members Carolyn Clancy, MD; ... member of both the Institute and the NPSF Board of ...
(Date:8/27/2014)... 27, 2014 CarePoint Health is ... Hoboken Pediatrics has joined our network, CarePoint Health ... Dr. Piotr Oko, Dr. Yanina Meshko and Dr. ... skilled and experienced physicians comprise CarePoint Health Medical ... practices in Hudson County, representing a wide range ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Driven by ... weatherstrip is expected to grow steadily during the next ... to reach 1.381 billion meters by end-2017. Tightness is ... seals are one of the most-used parts in an ... seals stood at 995 million meters, up just under ...
(Date:8/27/2014)... August 27, 2014 Scientists at The Scripps ... a specific signaling pathway can be associated with alcohol ... a gene, called neurofibromatosis type 1 (Nf1), which TSRI ... The new research shows Nf1 regulates gamma-aminobutyric acid (GABA), ... relaxation. , "This novel and seminal study provides ...
(Date:8/27/2014)... 27, 2014) Not all students returning to school ... vaccinations. A new study conducted by Jennifer Reich, a ... the reasons why children may not be fully vaccinated ... According to the National Network for Immunization Information, three ... any vaccines, with almost half of all children receiving ...
Breaking Medicine News(10 mins):Health News:NPSF President Among 100 Most Influential in Health Care 2Health News:NPSF President Among 100 Most Influential in Health Care 3Health News:Hoboken Pediatrics Joins CarePoint Health Medical Group 2Health News:Hoboken Pediatrics Joins CarePoint Health Medical Group 3Health News:Automobile Weatherstrip Sector in China Analysed in New SinoMarketInsight Research Study Published at MarketPublishers.com 2Health News:Automobile Weatherstrip Sector in China Analysed in New SinoMarketInsight Research Study Published at MarketPublishers.com 3Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:Expression of privilege in vaccine refusal 2
... On Thursday, January 8, Rhode Island Hospital treated ... as NanoKnife. Damian Dupuy, MD, director of ablation services ... ablation treatment, performed the procedure -- the first time ... the United States. , NanoKnife is an image-guided device ...
... Protica, Inc., the makers of the first capsulized ... to its product line. Following the FDA approval ... made with the natural sweetener will hit the ... the compact 2.9 fluid ounce beverage utilizes Actinase(R). ...
... Ill. and BATESVILLE, Ind., Jan. 9 ,Recognizing the ... excellent care at the patient,s bedside, Joint Commission,Resources ... are collaborating to launch a Nurse,Safety Scholar-in-Residence program ... Joint Commission. Hill-Rom is a global medical technology ...
... perception, reality , , FRIDAY, Jan. 9 (HealthDay News) -- ... their child,s eating and exercise habits, a new study ... Journal of Nutrition Education and Behavior that ... exercised well, while those with older children did not. ...
... Two words strike fear in the hearts of men and ... through the shock of that diagnosis, suffered the grief and ... the opportunity of a lifetime. In his new book, "Life ... AuthorHouse -- http://www.authorhouse.com ), he provides a valuable roadmap ...
... Mach One Corporation,(Pink Sheets: MNCN), a biological solutions ... benefit to the agricultural and consumer,market, announced today that ... January 7, 2009 related to a proposed transaction with ... the outstanding shares,of the Seller. , ...
Cached Medicine News:Health News:Rhode Island Hospital first in US to treat kidney tumor with new device using electrical pulses 2Health News:Protica Launches All-Natural Protein Beverage, Proasis 2Health News:JCR, Hill-Rom Launch Nurse Safety Scholar-in-Residence Program 2Health News:JCR, Hill-Rom Launch Nurse Safety Scholar-in-Residence Program 3Health News:Parents Not Best Barometer of Kid's Eating, Exercise Habits 2Health News:'Life Begins at 65: Words of a Cancer Survivor': New Book Offers Empowering Strategies for Rising Above Sickness and Setbacks 2Health News:'Life Begins at 65: Words of a Cancer Survivor': New Book Offers Empowering Strategies for Rising Above Sickness and Setbacks 3Health News:Mach One Corporation Enters Letter of Intent to Acquire Ceres Organic Harvest, Inc. 2
... Series from Thermo delivers maximum ... your low-speed clinical applications. With ... system, user-friendly controls, and generous ... Series delivers solid performance for ...
... CL30 Series from Thermo delivers ... for your low-speed clinical applications. ... exchange system, user-friendly controls, and ... CL30 Series delivers solid performance ...
Chembio Diagnostic Systems, Inc.s SURE CHECK HIV 1 / 2, HIV 1/ 2 STAT-PAK and HIV 1/ 2 STAT-PAK Dipstick tests are easy-to-perform, single-use diagnostic tests for the rapid, visual detection of anti...
When you use the optional REAL-Time Continuous Glucose Monitoring Kit with your insulin pump, you will have access to REAL-Time glucose readings, safety alarms, and glucose trend data around the cloc...
Medicine Products: